Finding the Best Stocks for Emerging Market ( PPHM, PURE, HEB, PGNX )

Los Angelas, CA -- (SBWIRE) -- 09/25/2012 -- Peregrine Pharmac (NCM:PPHM) is -4.23 - -78.48% from the previous close of $5.39. It traded between $0.80 - 1.57 with total traded volume of 68566656 shares. At Current Market Price, PPHM is in distance of -62.17% from its 50-day Moving Average price of $3.066 and -9.68% from its 200-day Moving Average price of $1.2843. Shares of Peregrine Pharmaceuticals Inc. (PPHM, $1.16, -$4.23, -78.48%) plunged after reporting that previously released results from a midstage cancer drug study aren't reliable because of a third-party error in conducting the study. The news erased a tenfold increase in the company's stock price this summer and removed almost a half-billion dollars in market value for the Tustin, Calif., drug maker. The company said investors should not rely on results from earlier this month, which stated that lung-cancer patients who took Bavituximab saw their median overall survival rate double over those who just took chemotherapy.

How Should Investors Trade KERX Now? Find Out Here

PURE Bioscience, (NCM:PURE) is very active today and traded between $1.0001 - 1.1801 with total traded volume of 1558962 shares. At a current price of 1.16, PURE is +0.17 - +17.17% from the previous close of $0.99. Moreover, At Current Market Price, PURE is in distance of -50.86% from its 50-day Moving Average price of $2.3606 and -54.95% from its 200-day Moving Average price of $2.5749. PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced it has regained compliance with Nasdaq listing requirements, and will continue trading on the Nasdaq Capital Market. On September 21, 2012, the Company received a letter from the Nasdaq Listing Qualifications Staff stating PURE Bioscience, Inc. has regained compliance with the applicable minimum shareholders' equity rule, as required by the Nasdaq Hearings Panel's decision dated June 21, 2012, as modified on August 10, 2012 and September 11, 2012. The Staff also concluded that the Company is in compliance with all other applicable requirements set forth in such decision and required for listing on The Nasdaq Capital Market. Accordingly, the Nasdaq Hearings Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and has closed this matter.

How Should Investors Trade KERX Now? Find Out Here

Hemispherx BioPha (AMEX:HEB) is very active today and traded between $0.88 - 1.10 with total traded volume of 14611428 shares. At a current price of 0.92, HEB is -0.08 - -8.00% from the previous close of $1.00. Moreover, At Current Market Price, HEB is in distance of +42.79% from its 50-day Moving Average price of $0.6443 and +129.67% from its 200-day Moving Average price of $0.4006. Hemispherx BioPharma, Inc(NYSEAMEX:HEB) shares jumped 9% to $1.09 after the company announced that the U.S. Food and Drug Administration has tentatively scheduled an Advisory Committee meeting to discuss the Ampligen(R) New Drug Application for Chronic Fatigue Syndrome which is currently under review by the FDA. The date of the AC review has been tentatively set for December 20, 2012. As previously announced, the Prescription Drug User Fee Act (“PDUFA”) review goal for the FDA to complete its review is February 2, 2013.

How Should Investors Trade KERX Now? Find Out Here

Shares of Progenics Pharmac (NasdaqNM:PGNX) are trading at $3.30 and is -17.04% from its 50-day Moving Average price of $3.9777 and -58.24% from its 200-day Moving Average price of $7.9016. The average trading volume is 317022 shares and its market capitalization is $111.8M. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) recently declared that it has cut about a quarter of its staff positions and is reducing back on research to save money. The firm eleminated27 jobs and reported that it will focus on an experimental prostate cancer drug while eliminating other programs.Progenics also reported that CFO Robert McKinney and Benedict Osorio, the firm’s senior vice president of quality, will leave the firm Sept. 30. The moves come concerning two months after the Food and Drug Administration reported it was not ready to grant a new marketing authorization to Relistor, a constipation drug Progenics licensed to Salix Pharmaceuticals Ltd.

How Should Investors Trade KERX Now? Find Out Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com